Carl,
The former of your options is true. Gel Tech's patent is for a method of delivery, as is Quigley's patent. The methods are different, Gel Tech's being for delivery through a nasal gel, and Quigley's being for delivery through oral mucosa. This is what many of us have been saying since Quigley filed their bogus lawsuit. The patent office basically verified this, albeit not with a legal ruling, when they approved Gel Tech's patent. Patents must be unique, and the Patent Office would not issue a new patent that conflicts with Quigley's patent. It is much more likely that Gel Tech will win a summary judgement now, if Quigley even proceeds with their ridiculous lawsuit.
Incidentally, the current rally began when the patent was approved and it looks like institutions are buying. With a growing short interest and institutions buying, I believe that shorts will get run over even more so than they already have been. The fundamentals support a much higher stock price, and GUMM is just beginning to get the respect that it has deserved for many months. Congratulations to all who had the patience to hold this stock and endure all the lies, misrepresentations, and scare tactics from short sellers for so many months.
Dan
PS to Robert: Thanks for the update on Wal*Mart, and best of luck in your new job. |
